Our mission is to reverse hypoxia. Hypoxia occurs when the body's cells don't get enough oxygen, this plays a significant role in various fatal diseases. We are committed to patient safety and ensuring their access to life-saving oxygen therapeutics.

NuvOx Therapeutics is a clinical stage pharmaceutical company developing a drug that improves the flow of oxygen from lungs to blood and from blood to tissue. Over 30 animal studies have shown therapeutic effect in seven different indications. Phase Ib/II clinical trials in stroke and oncology demonstrated safety and evidence of efficacy. The Company is currently enrolling 87 glioblastoma subjects in a prospective Phase IIb clinical trial to reverse tumor hypoxia; which increases radiation efficacy in association with chemoradiation treatment. The Company has received grant funding from NINDS to support evaluation of NanO₂ as a neuroprotectant by the Stroke Preclinical Assessment Network. The MHRA in the UK is supporting a Phase IIb clinical trial of NanO₂ in large vessel occlusion stroke. The trial will treat 150 stroke subjects and is scheduled to begin in 2024. BARDA is funding a Phase Ib clinical trial of NanO₂ in acute hypoxemic respiratory failure which will also start in 2024.